1. Home
  2. NAMS vs PRM Comparison

NAMS vs PRM Comparison

Compare NAMS & PRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • PRM
  • Stock Information
  • Founded
  • NAMS 2019
  • PRM 2018
  • Country
  • NAMS Netherlands
  • PRM United States
  • Employees
  • NAMS N/A
  • PRM N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • PRM Newspapers/Magazines
  • Sector
  • NAMS Health Care
  • PRM Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • PRM Nasdaq
  • Market Cap
  • NAMS 2.7B
  • PRM 2.9B
  • IPO Year
  • NAMS N/A
  • PRM N/A
  • Fundamental
  • Price
  • NAMS $26.73
  • PRM $22.04
  • Analyst Decision
  • NAMS Strong Buy
  • PRM Strong Buy
  • Analyst Count
  • NAMS 10
  • PRM 2
  • Target Price
  • NAMS $41.40
  • PRM $22.50
  • AVG Volume (30 Days)
  • NAMS 984.0K
  • PRM 1.4M
  • Earning Date
  • NAMS 11-05-2025
  • PRM 11-11-2025
  • Dividend Yield
  • NAMS N/A
  • PRM N/A
  • EPS Growth
  • NAMS N/A
  • PRM N/A
  • EPS
  • NAMS N/A
  • PRM 0.53
  • Revenue
  • NAMS $64,006,000.00
  • PRM $609,317,000.00
  • Revenue This Year
  • NAMS N/A
  • PRM N/A
  • Revenue Next Year
  • NAMS $1.67
  • PRM $6.70
  • P/E Ratio
  • NAMS N/A
  • PRM $41.38
  • Revenue Growth
  • NAMS 762.15
  • PRM 56.87
  • 52 Week Low
  • NAMS $14.06
  • PRM $8.76
  • 52 Week High
  • NAMS $27.35
  • PRM $23.79
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 59.23
  • PRM 63.21
  • Support Level
  • NAMS $23.05
  • PRM $20.89
  • Resistance Level
  • NAMS $27.35
  • PRM $22.65
  • Average True Range (ATR)
  • NAMS 1.52
  • PRM 0.81
  • MACD
  • NAMS -0.11
  • PRM -0.24
  • Stochastic Oscillator
  • NAMS 85.58
  • PRM 39.66

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About PRM Perimeter Solutions SA

Perimeter Solutions Inc is a solutions provider for the Fire Safety and Specialty Products industries. The Company's products and operations are managed and reported in two operating segments. Its Fire Safety segment provides fire retardants and firefighting foams, as well as specialized equipment and services typically offered in conjunction with the Company's retardant and foam products. The Specialty Products segment includes operations that develop, produce and market products for non-fire safety markets. Specialty Products segment is Phosphorus Pentasulfide (P2S5) based lubricant additives. P2S5 is also used in pesticide and mining chemicals applications, and emerging electric battery technologies.

Share on Social Networks: